19.01.2017 • NewsElaine BurridgeHuntsmanTiO2

Huntsman Retains Textiles, Names TiO2 Spin-Off

(c) Clicksi/Stockphoto
(c) Clicksi/Stockphoto

US chemical producer Huntsman has reconsidered and decided to exclude the textile effects business from the proposed spin-off of its titanium dioxide (TiO2) division.

Last August, CEO Peter Huntsman said the group was planning to add textile effects to the package as the business’s earnings were more stable than those for the pigment and would provide a buffer when TiO2 was in a trough.

Commenting on its about-turn, Huntsman said improved TiO2 prices as well as identified business improvement opportunities representing more than $75 million in annual EBITDA are expected to significantly enhance the financial strength of the spin-off. The $75 million in business improvements are incremental to current earnings and are expected to be completed by the end of 2018.

The company has also announced that the pigments spin-off will be called Venator Materials Corporation. The name – Venator is Latin for hunter – is partly intended to acknowledge the Huntsman legacy, the now Texas-headquartered group said. Shares are expected to trade on the New York Stock Exchange under the ticker VNTR after distribution to Huntsman’s shareholders, which remains targeted for the second quarter of 2017.

“We expect Venator will be a premier pigments company unencumbered by excessive debt or other unrelated liabilities,” said Huntsman. The company has been planning to separate its TiO2 business after acquiring Rockwood’s pigments and additives business in September 2014.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.